The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksItaconix Plc Regulatory News (ITX)

Share Price Information for Itaconix Plc (ITX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 157.50
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 15.00 (10.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 157.50
ITX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

5 May 2015 07:01

RNS Number : 0960M
Revolymer PLC
05 May 2015
 

5 May 2015

 

Revolymer plc ("Revolymer" or "the Group")

Awards under Long Term Incentive Plan and other share awards

 

Revolymer (AIM: REVO) announces the grant of awards under the Revolymer plc Long Term Incentive Plan ("LTIP") and other share awards to its executive directors Kevin Matthews and Robin Cridland.

 

The LTIP was adopted by the board of directors of Revolymer plc (the "Board") on 29 June 2012 and its remuneration committee has approved the following grants on 30 April 2015:

· To the CEO Kevin Matthews a nil cost option over 567,568 ordinary shares

· To the CFO Robin Cridland a nil cost option over 349,550 ordinary shares.

 

The vesting period of these grants is three years and they only become exercisable if challenging performance conditions are met; namely that 50% of the grant becomes exercisable if the weighted average ordinary share price in the 180 day period ending on the third anniversary of grant is £0.75. Between weighted average ordinary share prices of £0.75 and £1.00, vesting shall be pro-rata and on a straight line basis between 50% and 100%. Below £0.75 the grants are not exercisable and lapse in full.

 

The Board also requires the executive directors to maintain minimum interests (of at least 420,000 ordinary shares for Kevin Matthews and 388,000 ordinary shares for Robin Cridland) before selling any ordinary shares that are the result of exercise, except that they may sell that number of ordinary shares that are required to satisfy any income tax and employee's national insurance liabilities arising at exercise. This requirement shall not apply on a change of control, or other transaction with substantially the same effect.

 

Also on 30 April 2015, the Board authorised the issue to Robin Cridland of 36,036 fully paid up ordinary shares in Revolymer plc ("New Shares") in recognition of his fulfilment of the role of Acting CEO during 2014 before the arrival of Kevin Matthews. Following the issue of the New Shares, Mr Cridland will hold 52,836 ordinary shares representing approximately 0.1% per cent. of the Company's issued share capital.

 

Application has been made to the London Stock Exchange for the 36,036 New Shares to be admitted to trading on AIM ("Admission"). Admission is expected to occur at 8:00 am on 8 May 2015. Following Admission, the total number of ordinary shares in the Company will be 56,597,176 with each Ordinary Share carrying the right to one vote. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in ACR under the FSA's Disclosure and Transparency Rules.

 

Ends

 

For further information please contact:

Revolymer plc

+44 (0) 1244 283 500

Kevin Matthews / Rob Cridland

 

 

Panmure Gordon (UK) Limited

+44 (0) 20 7886 2500

Hugh Morgan / Adam James (Corporate Finance)

Charles Leigh-Pemberton (Corporate Broking)

 

 

About Revolymer

Revolymer is an AIM quoted company (registered number 08024489) that designs, develops and formulates novel polymers to improve the performance of its customers' and partners' products.

The vision for Revolymer is to build a high growth, high quality margin, specialty materials business based on proprietary polymer technology that provides responsive or smart multi-functional materials. The Board believes that the Company's technology has broad application. Revolymer aims to generate growing high quality revenue streams by either licensing its proprietary technologies or through the supply of proprietary products using an outsourced manufacturing model. Current target markets are Household Products, Personal Care and Nicotine Gum.

www.revolymer.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSEANSFEEXSEFF
Date   Source Headline
29th Apr 20247:00 amRNSLaunch of two plant-based performance ingredients
19th Apr 20247:00 amRNSGrants of Options & PDMR dealings
15th Apr 20247:00 amRNSPreliminary Results and Notice of AGM
8th Apr 20247:00 amRNSNotice of Results
2nd Apr 20247:00 amRNSTrading Statement
27th Feb 20247:00 amRNSTrading Update
9th Feb 20247:00 amRNSAppointment of Non-Executive Director
26th Jan 20247:00 amRNSAppointment: Nominated Adviser and Sole Broker
15th Dec 20237:00 amRNSDirector/PDMR Shareholding
15th Dec 20237:00 amRNSDirector/PDMR Shareholding
7th Dec 20237:00 amRNSTrading Update
30th Oct 20237:00 amRNSDirector/PDMR Shareholding
26th Oct 20235:28 pmRNSDirector/PDMR Shareholding
19th Oct 20235:08 pmRNSDirector/PDMR Shareholding
19th Oct 20237:00 amRNSDirector/PDMR Shareholding
5th Oct 202311:01 amRNSHoldings in Company
12th Sep 20237:00 amRNSHalf year results
5th Sep 20237:00 amRNSNotice of Interim Results and Presentations
22nd Aug 20237:00 amRNSShare Consolidation & Total Voting Rights
15th Aug 20237:00 amRNSShare Consolidation
12th Jul 20237:00 amRNSTrading Update
28th Jun 202312:29 pmRNSAGM Statement
5th Jun 20237:00 amRNSFinal Results
24th May 20237:00 amRNSNotice of Final Results, Briefings, and AGM
25th Apr 20237:00 amRNSAppointment of Joint Corporate Broker
2nd Mar 20233:25 pmRNSTR-1
1st Mar 20237:00 amRNSAward from Frost & Sullivan
28th Feb 20236:03 pmRNSTR-1
28th Feb 20235:04 pmRNSTR-1
28th Feb 20233:09 pmRNSTR-1
23rd Feb 20237:00 amRNSTR-1
22nd Feb 202312:28 pmRNSResults of Open Offer, GM and Total Voting Rights
15th Feb 20237:00 amRNSInvestor Presentation following GM on 22 Feb 2023
3rd Feb 20237:00 amRNSPlacing, Subscription and Open Offer; Notice of GM
5th Jan 20237:00 amRNSBoard Change
6th Dec 20224:40 pmRNSSecond Price Monitoring Extn
6th Dec 20224:35 pmRNSPrice Monitoring Extension
5th Oct 20227:00 amRNSItaconix and Brenntag Promote Sustainable Cleaning
14th Sep 20227:00 amRNSHalf year results
13th Sep 202211:05 amRNSSecond Price Monitoring Extn
13th Sep 202211:00 amRNSPrice Monitoring Extension
7th Sep 20227:00 amRNSNotice of Results
5th Sep 20227:00 amRNSItaconix and Croda Renew Supply Agreement
20th Jul 20227:00 amRNSBoard Change
13th Jul 20227:00 amRNSTrading Update
5th Jul 20227:00 amRNSDirectorate Change
1st Jul 20222:37 pmRNSResult of AGM
1st Jul 20229:00 amRNSPrice Monitoring Extension
1st Jul 20227:00 amRNSAGM Statement and Notice of Capital Markets Event
29th Jun 20227:00 amRNSNotice of Capital Markets Webinar

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.